Efficacy and Safety of Apatinib Plus Vinorelbine in Patients With Wild-Type Advanced Non–Small Cell Lung Cancer After Second-Line Treatment Failure-Reference-Cited by-同舟云学术

Efficacy and Safety of Apatinib Plus Vinorelbine in Patients With Wild-Type Advanced Non–Small Cell Lung Cancer After Second-Line Treatment Failure

Published:2020-03-19 Issue:3 Volume:3 Page:e201226
ISSN:2574-3805
Container-title:JAMA Network Open
language:en
Short-container-title:JAMA Netw Open

Author:

Zhang Xiangyu¹,Xiong Yi¹,Xia Qing²,Wu Fang¹³,Liu Lingli¹²,Zhou Yuling¹²,Zeng Liang¹,Zhou Chunhua¹,Xia Chen⁴,Jiang Wenjuan¹,Liao Dehua⁵,Xiao Lili¹,Liu Li¹,Yang Haiyan¹,Guan Rui¹,Li Kunyan⁶,Wang Jing⁷,Lei Guang⁸,Zhang Yongchang¹,Yang Nong¹

Affiliation:

1. Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China

2. State Key Laboratory for Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Department of Oncology, Shanghai Jiao Tong University School of Medicine, Shanghai, China

3. Graduate Schools, University of South China, Hengyang, China

4. Department of Hepatology, Hunan Cancer Hospital, Changsha, China

5. Department of Pharmacy, Hunan Cancer Hospital, Changsha, China

6. Center of New Drug Clinical Trials, Hunan Cancer Hospital, Changsha, China

7. Hunan Clinical Research Center in Gynecologic Cancer, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China

8. Department of Experimental Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2762949/zhang_2020_oi_200069.pdf

Reference25 articles.

1. Cancer statistics, 2018.;Siegel;CA Cancer J Clin,2018

2. Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics?;Feng;Cancer Commun (Lond),2019

3. Stage IV EGFR mutation-negative and ALK mutation-negative lung adenocarcinoma: long-term survival is possible.;Kedia;Cureus,2015

4. Retrospective efficacy and safety analyses of erlotinib, pemetrexed, and docetaxel in EGFR-mutation-negative patients with previously treated advanced non-squamous non-small-cell lung cancer.;Nishiyama;Lung Cancer,2015

5. Effectiveness of erlotinib treatment in advanced KRAS mutation-negative lung adenocarcinoma patients: results of a multicenter observational cohort study (MOTIVATE).;Sarosi;Lung Cancer,2014

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring treatment options in cancer: tumor treatment strategies;Signal Transduction and Targeted Therapy;2024-07-17

2. Tilianin enhances the antitumor effect of sufentanil on non‐small cell lung cancer;Journal of Biochemical and Molecular Toxicology;2024-07

3. The efficiency and safety of low‐dose apatinib combined with oral vinorelbine in pretreated HER2‐negative metastatic breast cancer;Cancer Medicine;2024-04

4. Apatinib plus chemotherapy is associated with an improved tumor response, survival and tolerance compared with chemotherapy alone for advanced lung adenocarcinoma treatment;Oncology Letters;2024-03-05

5. Efficacy and safety of apatinib combined with liposomal doxorubicin or paclitaxel versus liposomal doxorubicin or paclitaxel monotherapy in patients with recurrent platinum‐resistant ovarian cancer;Journal of Obstetrics and Gynaecology Research;2023-03-29